@article {MATSUMOTO3029, author = {FUMIHIKO MATSUMOTO and DAVID N. VALDECANAS and KATHRYN A. MASON and LUKA MILAS and K. KIAN ANG and UMA RAJU}, title = {The Impact of Timing of EGFR and IGF-1R Inhibition for Sensitizing Head and Neck Cancer to Radiation}, volume = {32}, number = {8}, pages = {3029--3035}, year = {2012}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Targeting the epidermal growth factor receptor (EGFR) improved radiotherapy outcome by 10-15\% in head and neck tumors (HNSCC). We tested the therapeutic benefits of co-targeting EGFR and insulin-like growth factor-1 receptor (IGF-1R) to further enhance tumor response to radiation. Materials and Methods: Mice bearing FaDu tumor xenografts were treated with ganitumab (previously known as AMG479, an anti-IGF-1R antibody), panitumumab (an anti-EGFR antibody), or both in combination with fractionated doses of radiation. Tumor growth delay and tumor cure/recurrence served as end-points. Results: The best tumor growth delay was achieved when ganitumab and panitumumab were given concurrently with radiation. Tumor cure/recurrence studies showed that combining ganitumab, panitumumab and radiation resulted in significantly higher radiocurability rates than use of either of the agents given with radiation. Conclusion: These findings provide the rationale for clinical testing of the combination of ganitumab and panitumumab for the treatment of HNSCC.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/32/8/3029}, eprint = {https://ar.iiarjournals.org/content/32/8/3029.full.pdf}, journal = {Anticancer Research} }